• Product nameAnti-Vimentin antibody [Vim 3B4]
    See all Vimentin primary antibodies
  • Description
    Mouse monoclonal [Vim 3B4] to Vimentin
  • SpecificityAb28028 recognises Vimentin
  • Tested applicationsWB, IHC-Fr, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Rabbit, Horse, Chicken, Hamster, Cow, Dog, Human, Xenopus laevis
  • Immunogen

    Full length native protein (purified): Vimentin isolated from bovine eye lens.

  • EpitopeAb28028 reacts with an epitope located in the coil 2 part of the vimentin rod domain.
  • Positive control



Our Abpromise guarantee covers the use of ab28028 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/200. Predicted molecular weight: 54 kDa.
IHC-Fr 1/100 - 1/200. The antibody can be used for labeling acetone fixed, frozen sections.
IHC-P 1/100 - 1/200. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.


Anti-Vimentin antibody [Vim 3B4] images

  • ab28028 staining of tonsil by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections).

  • ab28028 staining of tonsil by Immunohistochemistry(Formalin-fixed paraffin-embedded sections)

  •  ab28028 at 1/200 dilution staining vimentin in human lung cancer cells. The Vimentin staining is shown in red. The cells were counterstained with DAPI. Please see accompanying abreview for additional information.

    See Abreview

  • ab28028 staining Vimentin in human fibrosarcoma cells by Immunocytochemistry/ Immunofluorescence. Cells were fixed with paraformaldehyde, permeabilized with 1% Triton x100. Samples were incubated with primary antibody (1/100) for 1 hour at 20°C. An Alexa Fluor®488-conjugated donkey monoclonal to mouse IgG (ab150105) was used at dilution at 1/500 as secondary antibody.

    See Abreview

References for Anti-Vimentin antibody [Vim 3B4] (ab28028)

This product has been referenced in:
  • Buchholz M  et al. A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer. PLoS One 10:e0122946 (2015). ICC . Read more (PubMed: 25849100) »
  • Beaudet MJ  et al. High yield extraction of pure spinal motor neurons, astrocytes and microglia from single embryo and adult mouse spinal cord. Sci Rep 5:16763 (2015). Read more (PubMed: 26577180) »

See all 10 Publications for this product

Product Wall

Merci de nous avoir contactés.

L'anticorps prédilué ab82612 (Anti-Cytokeratin [MNF116]) a une concentration entre 1 et 3 µg/ml.
L'anticorps ab28028 (Anti-Vimentin [Vim 3B4]) est un supernageant, la concentration ...

Read More

Thank you for contacting us.

We have 4, FITC conjugated anti Glycophorin A antibodies.


Read More

Thank you for your inquiry.

For ab758, the immunogen that was used was cytoskeletal extract of human hepatocellular carcinoma cell line, Hep3B. We have not validated this antibody in pig. But the human sequence is 85% homologous with the pig ...

Read More

Thank you for contacting us and your interest in our products.

We have several antibodies directed against epithelial membrane antigen (also known as MUC1), however only one has been teated in all the applications you wish to use it for...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (fibrosarcoma)
Specification fibrosarcoma
Fixative Paraformaldehyde
Permeabilization Yes - 1% TX-100

Abcam user community

Verified customer

Submitted Oct 16 2009

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (Lung cancer)
Specification Lung cancer
Fixative Paraformaldehyde
Permeabilization Yes - 0.2% Triton
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: RT°C

Dr. Da Zhu

Verified customer

Submitted Mar 26 2009